---
pmid: '34811497'
title: HIV-1 Vif suppresses antiviral immunity by targeting STING.
authors:
- Wang Y
- Qian G
- Zhu L
- Zhao Z
- Liu Y
- Han W
- Zhang X
- Zhang Y
- Xiong T
- Zeng H
- Yu X
- Yu X
- Zhang X
- Xu J
- Zou Q
- Yan D
journal: Cell Mol Immunol
year: '2022'
full_text_available: false
pmcid: PMC8752805
doi: 10.1038/s41423-021-00802-9
---

# HIV-1 Vif suppresses antiviral immunity by targeting STING.
**Authors:** Wang Y, Qian G, Zhu L, Zhao Z, Liu Y, Han W, Zhang X, Zhang Y, Xiong T, Zeng H, Yu X, Yu X, Zhang X, Xu J, Zou Q, Yan D
**Journal:** Cell Mol Immunol (2022)
**DOI:** [10.1038/s41423-021-00802-9](https://doi.org/10.1038/s41423-021-00802-9)
**PMC:** [PMC8752805](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752805/)

## Abstract

1. Cell Mol Immunol. 2022 Jan;19(1):108-121. doi: 10.1038/s41423-021-00802-9.
Epub  2021 Nov 22.

HIV-1 Vif suppresses antiviral immunity by targeting STING.

Wang Y(#)(1)(2)(3), Qian G(#)(1), Zhu L(#)(1), Zhao Z(#)(2), Liu Y(1), Han W(4), 
Zhang X(2), Zhang Y(1), Xiong T(2), Zeng H(2), Yu X(5), Yu X(6), Zhang X(1), Xu 
J(7), Zou Q(8), Yan D(9).

Author information:
(1)Department of Immunology, School of Basic Medical Sciences, Shanghai 
Institute of Infectious Disease and Biosecurity & Shanghai Public Health 
Clinical Center, Fudan University, Shanghai, 200032, China.
(2)National Engineering Research Centre of Immunological Products, Department of 
Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical 
University, Chongqing, 400038, China.
(3)Department of Basic Courses, NCO School, Army Medical University, 
Shijiazhuang, 050081, China.
(4)Biosafety Level 3 Laboratory, Fudan University, Shanghai, 200032, China.
(5)National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, 
Jilin University, Changchun, 130012, China.
(6)Institute of Virology and AIDS Research, The First Hospital of Jilin 
University, Changchun, 130061, China.
(7)Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital & 
Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China. 
xujianqing@shphc.org.cn.
(8)National Engineering Research Centre of Immunological Products, Department of 
Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical 
University, Chongqing, 400038, China. qmzou2007@163.com.
(9)Department of Immunology, School of Basic Medical Sciences, Shanghai 
Institute of Infectious Disease and Biosecurity & Shanghai Public Health 
Clinical Center, Fudan University, Shanghai, 200032, China. 
dapengyan@fudan.edu.cn.
(#)Contributed equally

HIV-1 infection-induced cGAS-STING-TBK1-IRF3 signaling activates innate immunity 
to produce type I interferon (IFN). The HIV-1 nonstructural protein viral 
infectivity factor (Vif) is essential in HIV-1 replication, as it degrades the 
host restriction factor APOBEC3G. However, whether and how it regulates the host 
immune response remains to be determined. In this study, we found that Vif 
inhibited the production of type I IFN to promote immune evasion. HIV-1 
infection induced the activation of the host tyrosine kinase FRK, which 
subsequently phosphorylated the immunoreceptor tyrosine-based inhibitory motif 
(ITIM) of Vif and enhanced the interaction between Vif and the cellular tyrosine 
phosphatase SHP-1 to inhibit type I IFN. Mechanistically, the association of Vif 
with SHP-1 facilitated SHP-1 recruitment to STING and inhibited the K63-linked 
ubiquitination of STING at Lys337 by dephosphorylating STING at Tyr162. However, 
the FRK inhibitor D-65495 counteracted the phosphorylation of Vif to block the 
immune evasion of HIV-1 and antagonize infection. These findings reveal a 
previously unknown mechanism through which HIV-1 evades antiviral immunity via 
the ITIM-containing protein to inhibit the posttranslational modification of 
STING. These results provide a molecular basis for the development of new 
therapeutic strategies to treat HIV-1 infection.

Â© 2021. The Author(s), under exclusive licence to CSI and USTC.

DOI: 10.1038/s41423-021-00802-9
PMCID: PMC8752805
PMID: 34811497 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing interests.
